PCSK9 and ischemic stroke: Additionally, findings from the FOURIER and ODYSSEY OUTCOMES clinical trials demonstrated a significant reduction in the risk of cerebrovascular disease, encompassing both ischemic stroke and recurrent ischemic stroke, with the utilization of PCSK9 inhibitors.